pharma-ai
(2)
Dimitrios Skaltsas
Dimitrios Skaltsas is the co-founder and CEO of Intelligencia AI, a New York enterprise software company that uses machine learning and curated biomedical data to estimate the probability that a drug candidate will win regulatory approval. Trained as a lawyer in Athens and London, he spent more than a decade at McKinsey, where he built and led New Ventures' big-data and AI work for pharmaceutical R&D before co-founding Intelligencia with Vangelis Vergetis in 2017. Under his leadership the company raised a Series A, was named one of Forbes's Top AI Companies to Watch, secured a U.S. patent for its probability-of-success assessments, and landed on the Inc. 5000. He is also an Executive in Residence at INSEAD.
Doron Aspitz
Doron Aspitz is the President and CEO of Verix, a Santa Clara-based AI platform that helps pharmaceutical companies optimize their commercial operations through predictive analytics, HCP targeting, and GenAI-powered decision intelligence. A serial entrepreneur with 20+ years in technology leadership, he previously co-founded Blue Pumpkin Software - a workforce management company acquired by Witness Systems for ~$75 million in 2005. At Verix, he has built the Tovana platform, now trusted by global pharma giants including Bayer, Novartis, Roche, and GSK, bringing AI-driven commercial intelligence to the complex world of drug commercialization.